| Document |
Document Title |
|
WO/2005/065361A2 |
Compounds are disclosed with activity towards killing dysproliferative cells in vitro and treating cancer in vivo. Cancers such as cancer of the colon, pancreas, prostate, lung, breast, urinary bladder, skin and liver are exemplary. Comp...
|
|
WO/2005/063222A1 |
An Hsp90 family protein inhibitor which contains as an active ingredient a benzene derivative represented by the following general formula (I), a prodrug thereof, or a pharmacologically acceptable salt of either.
|
|
WO/2005/063018A1 |
Present invention relates to a haloalkene compound of the formula (I)or its salt: wherein each of X1 and X2 is halogen; Y is alkyl, haloalkyl or phenyl; n is 0 to 5; L is -C(=B)Q, -C(=B)B’Q, -C(=B)N(D)Q, -N(D)Q, -N(D)C(=B)Q, -N(D)C(=B)...
|
|
WO/2005/058806A1 |
A method for producing chlorosulfonyl isocyanate wherein chlorocyanogen is reacted with sulfur trioxide to form chlorosulfonyl isocyanate, characterized in that chlorosulfonyl isocyanate or a fluid containing chlorosulfonyl isocyanate is...
|
|
WO/2005/044787A1 |
Compounds of formula (I) and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective β2-adrenoreceptor agonist is indicated, for example ...
|
|
WO/2005/037774A1 |
This invention relates to a novel class of acidic amino acid/dicarboxylic acid derivatives (sulfonic acid/sulfate derivatives of naturally occurring amino acids and their amides) useful as inhibitors of osteoclastogenesis. The invention ...
|
|
WO/2005/037775A1 |
The present invention is related to compound having general formula Z-OC (C Rn1Rn2) -CO-Z wherein Z &equals OH or NH2 and n1 &equals n2 &equals 1 to useful for modulation of immune response by inducing differentiation of dendritic cells ...
|
|
WO/2005/037776A1 |
The present invention is related to compound having general formula Z-OC (C Rn1Rn2) -CO-Z wherein Z = OH or NH2 and n1 = n2 = 1 to 8 for modulation of immune response by inducing differentiation of dendritic cells consisting novel class ...
|
|
WO/2005/035514A2 |
The present invention provides compounds of Formula (I) useful as modulators of ABC transporter activity, or a pharmaceutically acceptable salt thereof, wherein RB, n, B, RC, RD, RE, A, and Z are described generally and in classes and su...
|
|
WO/2005/016862A1 |
A compound represented by the formula (I)[In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting car...
|
|
WO/2004/113278A2 |
Compounds having the general formula (I) are useful for inhibiting serine protease enzymes, such as Tissue Factor VIIa, factor Xa, thrombin and kallikrein and have improved permeability properties. These compounds may be used in methods ...
|
|
WO/2004/113277A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-+ related disease.
|
|
WO/2004/113275A2 |
Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
|
|
WO/2004/099126A1 |
Compounds of formula (I): wherein the various symbols are as defined and salts thereof are described as integrin &agr 4-antagonists.
|
|
WO/2004/087720A1 |
Phosphate/sulfate ester compounds that modulate and/or inhibit the activity of protein interacting NIMA (PIN1), and to pharmaceutical compositions containing such compounds are described. The invention is also directed to the therapeutic...
|
|
WO/2004/080389A2 |
The present invention provides a hydroxyeicosadienamide compound an excellent inhibitory effect on elastase release, which is represented by Formula (I): (I), wherein n represents an integer of 0 to 5, and R represents an optionally subs...
|
|
WO/2004/074238A1 |
Compounds of formula (I): (I)are effective in the treatment of protein tyrosine phosphatase (PTPase) mediated disorders such as diabetes.
|
|
WO/2004/074256A1 |
Compounds of formula (I): (I)are effective in the treatment of protein tyrosine phosphatase (PTPase) mediated disorder such as diabetes.
|
|
WO/2004/065353A1 |
The present invention is related to a compound of formula (I): A-B-E-D (I), wherein: A is selected from the group consisting Ra-L1-K-L2; and (II) B is either present or absent, but if B is present then B is (III), E is (IV), D is selecte...
|
|
WO/2004/062594A2 |
Ether lipid compounds of formula (I), pharmaceutically-acceptable salts, prodrugs or isomers thereof are provided, where the variables are as defined herein. The compounds of the invention have anti-neoplastic activity, and accordingly h...
|
|
WO/2004/052847A2 |
The present invention relates to methods of treating pathological disorders susceptible to steroid hormone nuclear receptor modulation comprising administering to a patient in need thereof an effective amount of a compound of the formula...
|
|
WO/2004/039768A1 |
The invention relates to a method for producing phenyliso(thio)cyanates of general formula (I) according to which a compound of general formula (II) or the HCl adduct thereof is reacted with a phosgenating agent, wherein W represents oxy...
|
|
WO/2003/097589A1 |
The invention relates to a method for the production of sulphamic acid halogenides of primary or secondary amines, comprising the following steps: i) reaction of a primary or secondary amine A1 with at least equimolar amounts of SO3 or a...
|
|
WO/2003/091204A1 |
The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use i...
|
|
WO/2003/091207A2 |
This invention provides a method of preparing amine stereoisomers, which comprises stereoselectively reducing a sulfinylimine that bears on the sulfmyl group a residue of an alcohol, thiol or amine, or reacting a sulfmylimine stereoisome...
|
|
WO/2003/082263A1 |
The present invention relates to certain substituted sulfamic acids, which exhibit inhibitory action against Human Cytoplasmic Protein Tyrosine Phosphatases (HC-PTPs, Low Molecular Weight Protein Tyrosine Phosphatases, Orthophosphoric Mo...
|
|
WO/2003/070686A1 |
A compound represented by the general formula (I):[wherein n is an integer of 1 to 3; R represents C3-8 alkyl, a group represented by R1(CH2)k- (k is an integer of 0 to 3; and R1 represents C3-7 saturated cycloalkyl or C6-8 fused-ring sa...
|
|
WO/2003/068732A2 |
The invention provides compounds of formula (I) wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifl...
|
|
WO/2003/066549A2 |
A regio- and stereoselective two-stage synthesis of β-aminoalcohols employs a key transformation, viz., the creation of a cyclic sulfamidate from a precursor diol, mediated by Burgess-type reagents. The generality and scope of this appr...
|
|
WO/2003/063797A2 |
Novel cycloalkyl compounds useful as inhibitors of potassium channel function (especially inhibitors of the Kv1subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating dela...
|
|
WO/2003/053992A2 |
This invention describes a safe method for the production of sulfamoyl chloride from chlorosulfonyl isocyanate and formic acid in the presence of a amide catalyst, taming the hazardous nature of this reaction by circumventing heat accumu...
|
|
WO/2003/051841A2 |
Carbamates and related compounds of formula R1 R2NCO-Y or R1 R2NCS-Y wherein R1 and R2 are hydrogen, alkyl, aryl, heteroaryl or may together form a piperidine, piperazine, morpholine or other heterocyclic ring, are inhibitors of hormone ...
|
|
WO/2003/051842A2 |
Carbamates and related compounds of formula R1R2NCO-Y or R1R2NCS-Y wherein R1 and R2 may form a ring, are inhibitors of hormone sensitive lipase and are useful for the treatment of any disorder where it is desirable to modulate the plasm...
|
|
WO/2003/043625A1 |
(R) and (S) 2-Aryl-propionic acids, and pharmaceutical compositions that contain them, are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR...
|
|
WO/2003/027059A1 |
Acid amide derivatives represented by the formula (I) (I) [wherein A is phenyl optionally substituted by X, benzyl optionally substituted by X, naphthyl optionally substituted by X, a heterocyclic group optionally substituted by X, a fus...
|
|
WO/2003/020690A1 |
Aryl sulfamate derivatives represented by the general formula (&Verbar ) or pharmacologically acceptable salts thereof: (&Verbar ) wherein Rr and Rs are each independently hydrogen or lower alkyl&semi R1, R2, R3, and R4 are each independ...
|
|
WO/2003/004461A1 |
A series of imidodisulfamide derivatives have been prepared and are useful to treat antiviral infections, especially infections caused by orthopox viruses.
|
|
WO/2003/002525A1 |
The invention relates to novel pesticidally active N-bisaryl- and N-aryl-cycloalkylidenyl-$g(a)-sulfin- and $g(a)-sulfonamino acid amides of the general formula I, including the optical isomers thereof and mixtures of such isomers, where...
|
|
WO/2002/100804A2 |
The invention relates to the use of chiral sulfamic acids as resolving agents, the sulfamic acid having the formula (R¿1?, R¿2?) N-SO¿3H?, wherein: R¿1? and R¿2?, being the same or different, represent a hydrogen atom or a C¿1-?C¿...
|
|
WO/2002/098847A1 |
The present invention provides certain cycloalkenylsulfonamide derivatives of the formula: useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiat...
|
|
WO/2002/076375A2 |
The present invention relates to an improved process for the preparation of trifluoromethanesulfonic ester of ethyl (R)-2-hydroxy-4-phenylbutyrate, referred to here as triflate in structural Formula I, and to the use of this compound as ...
|
|
WO/2002/064550A1 |
Compounds of formula (I) (I), or pharmaceutically acceptable salts thereof are novel glucocorticoid receptor modulators and are useful for treating type II diabetes in a mammal.
|
|
WO/2002/064136A2 |
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases m...
|
|
WO/2002/058690A2 |
The present invention relates to methods for the prophylaxis, management and treatment of certain diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD) by the administration ...
|
|
WO/2002/058698A2 |
The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases m...
|
|
WO1999059957A9 |
Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparatio...
|
|
WO/2002/036555A1 |
Novel sulfamides of formula (I) are disclosed. The compounds exert an inhibitory action on the processing of APP by gamma-secretase, and are therefore useful in the treatment or prevention of Alzheimer's disease.
|
|
WO/2002/034722A1 |
New 1,2,3- or 1,2,3,4- or 1,2,3,4,5- substituted imidazolium salts and their uses as solvent in catalysed organic reactions, as well as compositions containing them and a transition metal compound. They can be used in the following react...
|
|
WO/2002/032858A1 |
The present invention provides compounds of formula (I): useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
|
|
WO/2002/024644A1 |
The invention relates to novel $g(D)?1¿ pyrrolines of formula (I), wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, n, r and s have the meanings given in the description, to several methods for producing these substances, to their use for con...
|
